Ultraviolet recall dermatitis reaction with sorafenib.
OBJECTIVE
Recall dermatitis is a rare and poorly understood drug-related event. Activated by exposure to sunlight or Ultraviolet (UV), drug-related phototoxic reactions have been reported with conventional chemotherapy agents or antibiotics.


METHODS
Here, we report the first case of acute dermatologic photo-induced recall reaction secondary to sorafenib in a patient with renal cell carcinoma.


RESULTS
Four weeks after stopping sorafenib, a patient with renal cell carcinoma developed an acute erythematous and papulomatous eruption restricted to the hands after prolonged solar exposure. The erythematous region was very well demarcated, mimicking the cutaneous syndrome that the patient had presented at time he was receiving sorafenib.


CONCLUSIONS
The suppression of the phototoxic reaction by corticosteroids strongly suggests that the immune system may have an important function in photo-recall reactions.
Magné
Nicolas
N
Department of Radiotherapy, Institut de Cancérologie de la Loire, 108 bis, avenue Albert Raimond, BP 60008, 42271 Saint Priest en Jarez, France. nicolas.magne@icloire.fr
Chargari
Cyrus
C
Auberdiac
Pierre
P
Moncharmont
Coralie
C
Merrouche
Yacine
Y
Spano
Jean-Philippe
JP
D001557:Benzenesulfonates / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011855:Radiodermatitis / Q000139:chemically induced*; D000077157:Sorafenib; D014466:Ultraviolet Rays / Q000009:adverse effects*
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib